General inflammation markers such as C-Reactive Protein are often checked alongside the result, although they can sit inside the standard range even while symptoms are active. The sections below cover what the gene does, what a positive result changes, what is worth watching for, and when to bring it to a clinician.
HLA-B27 is one of many normal versions of the HLA-B gene, which helps the immune system tell your own healthy cells apart from infected or abnormal ones. The HLA system (human leukocyte antigen) sits on chromosome 6 and is one of the most variable parts of the human genome. HLA-B belongs to the class I group, and its protein product appears on the surface of almost every nucleated cell in the body.
The job of a class I molecule is display. It picks up short protein fragments from inside the cell and holds them out on the cell surface, where patrolling immune cells inspect them. If the fragments look like they came from a virus or a damaged cell, the immune system responds. If they look like ordinary self proteins, it moves on. HLA-B27 does this job like any other HLA-B version, it simply has a slightly different groove shape, so it binds and displays a slightly different set of fragments.
Two things follow from that. First, carrying HLA-B27 is not a defect or a mutation, it is an inherited variant that works. Second, the variant is present from conception and does not change, so the result from a single test holds for life. What makes it clinically interesting is that HLA-B27 is associated with a family of inflammatory conditions known as spondyloarthritis 1.
A positive result means you carry at least one copy of the HLA-B27 variant, and nothing more than that. It is a risk marker, not a measurement of disease and not a measurement of how much inflammation you have today. Two people with identical positive results can have completely different clinical pictures, because the gene only shifts probability.
It helps to read the result in three steps. The observation is simple, the typing test detected the HLA-B27 variant in your blood. The possible meaning is that your background odds of certain inflammatory conditions, particularly inflammation of the spine and sacroiliac joints and a specific kind of eye inflammation, are higher than those of a non carrier. The next step is where the value sits, which is a conversation about whether you have any symptom pattern that would make the result relevant, and whether examination or imaging is worth arranging.
Clinicians usually order the test because something already prompted the question, for example persistent back pain that behaves oddly, a recurrent painful red eye, or joint symptoms after a gut or urinary infection. In that setting the result is one supporting piece of evidence among several. Ordered without any symptoms, a positive result mostly buys awareness. It does not, on its own, justify a diagnosis, and treatment decisions belong to a licensed provider who has examined the whole picture.
Most people who carry HLA-B27 stay well because one gene variant is rarely enough on its own. The variant is common in the general population, far more common than the conditions it travels with, which tells you immediately that carrying it is not sufficient to cause disease.
Research suggests that other inherited factors, the gut microbiome and mechanical stress at the points where tendons and ligaments attach to bone all contribute to spondyloarthritis alongside HLA-B27 2. In other words, the gene appears to set a threshold rather than pull a trigger, and whether that threshold is crossed depends on biology you cannot read off a single typing test.
This is why a positive result should not be experienced as a countdown. A useful comparison is a family history of a condition. It changes what you and your clinician pay attention to, it does not script the future. People who carry the variant and have no symptoms are generally not monitored intensively, they are simply told which symptom patterns would be worth reporting.
It also explains why the test has limited value as a screening tool in people without symptoms. A positive result in someone with no complaints cannot be acted on, and a negative result in someone with classic inflammatory symptoms does not close the case. The test earns its keep when there is a clinical question in front of it.
The leading explanations centre on what the HLA-B27 molecule does differently, both when it displays fragments normally and when it behaves abnormally inside the cell. Research suggests that the HLA-B27 molecule may influence inflammatory disease through the specific peptides it presents, through a tendency of its heavy chain to misfold inside the cell, and through unusual surface forms that engage receptors on immune cells 1.
One idea is about mistaken identity. Because the HLA-B27 groove binds a distinctive set of peptide fragments, an immune response aimed at a microbial fragment could in principle also recognise a similar looking self fragment. Another idea is about cell stress. HLA-B27 heavy chains fold slowly, and accumulated misfolded protein can push a cell into a stress response that releases inflammatory signals. A third involves free heavy chains that pair up on the cell surface in forms that ordinary HLA molecules do not adopt, which can be read by receptors on natural killer cells and certain T cells.
Research suggests that HLA-B27 sits at the meeting point of innate and adaptive immunity, with the interleukin 23 and interleukin 17 signalling pathway and tissue level factors contributing to how spondyloarthritis develops 3. The practical takeaway for a reader is modest but real. The inflammation associated with this variant is immune driven and tends to concentrate in specific tissues, which is why symptoms cluster at the spine, the sacroiliac joints, tendon insertions, the gut and the front of the eye rather than appearing at random.
The strongest association is with axial spondyloarthritis, the group of conditions that includes ankylosing spondylitis, where inflammation affects the sacroiliac joints and the spine. HLA-B27 is associated with spondyloarthritis more strongly than almost any other gene variant is associated with a common condition 1.
Several related presentations belong to the same family. Peripheral spondyloarthritis affects joints in the limbs and the entheses, the attachment points of tendon to bone, and often shows up as heel pain, a swollen finger or toe, or an asymmetric lower limb arthritis. Reactive arthritis follows certain gut or urinary tract infections by days to weeks. Arthritis occurring in people with inflammatory bowel disease and spinal involvement in people with psoriasis both sit in the same group. Acute anterior uveitis, inflammation at the front of the eye, is associated with HLA-B27 positivity 4.
Two cautions matter here. First, these conditions overlap, and one person may show features of more than one over time. Second, the presence of the gene variant does not grade severity. Some people have mild, intermittent symptoms for decades, others have a more persistent course, and the variant alone does not predict which. Diagnosis in every case rests on the pattern of symptoms, the physical examination and imaging, with the gene result used as supporting information rather than as the deciding factor.
Inflammatory back pain follows a pattern that is close to the opposite of mechanical back pain, which is why clinicians ask such specific questions. The features that raise suspicion include the following.
Ordinary mechanical back pain usually behaves the other way around. It is often triggered by a particular movement, it worsens through the day with activity, it settles with rest, and morning stiffness is brief.
Other clues sit outside the back. Persistent heel pain at the Achilles insertion or under the heel, a whole finger or toe swelling rather than a single joint, recurrent painful red eye, psoriasis, and long running diarrhoea or blood in the stool all belong on the same checklist.
None of this is self diagnosis material. The point of recognising the pattern is to describe it accurately to a clinician, because the description is what prompts the right examination and the right imaging. Imaging of the sacroiliac joints and the spine, together with the examination, carries more weight in a diagnosis than any gene result.
A painful, red, light sensitive eye with blurred vision deserves same day assessment, especially in someone who carries this variant. Acute anterior uveitis is associated with HLA-B27 and typically affects one eye at a time, starts suddenly over hours to a couple of days, and tends to recur, sometimes alternating between eyes 4.
The symptoms are distinctive once you know them. Deep aching pain in or around the eye, marked discomfort in bright light, redness that is most intense in the ring around the coloured iris, watering, and vision that becomes hazy rather than simply blurry at distance. Itching and thick discharge point elsewhere, they are more typical of surface irritation or infection.
Research on HLA-B27 positive anterior uveitis describes a recurrent course and emphasises coordinated care between eye specialists and rheumatology, since the eye episode can be the first visible sign of a wider spondyloarthritis 5. That coordination cuts both ways. Someone whose first episode is in the eye may later describe inflammatory back pain, and someone with known back involvement who develops eye symptoms should say so rather than wait.
The practical rule is simple. Eye symptoms of this kind are worth discussing with a clinician promptly, on the same day if possible, because assessment of the front of the eye needs equipment you do not have at home. Any decision about management belongs to a licensed provider who can examine the eye directly.
Heart involvement is uncommon, but it is recognised and worth knowing about. HLA-B27 is associated with disease of the aortic root and valve and with disturbances of the heart's electrical conduction system, including atrioventricular block 6. Research describes this pattern mainly in men and more often with long standing disease 6.
What that means in daily life for most carriers is very little. The large majority of people who carry the variant never develop any cardiac issue, and there is no routine cardiac screening recommended simply because a typing test came back positive. The reason to mention it at all is symptom literacy. Unexplained breathlessness on exertion, episodes of light headedness or fainting, a new persistently slow pulse or palpitations are worth reporting to a clinician rather than filed under tiredness, particularly in someone with long standing spondyloarthritis.
The same applies to a new heart murmur picked up at a routine examination. It is usually not related, but the context is relevant information for whoever is assessing it, so mention the positive result when you describe your history.
This is one of several reasons to keep an accurate personal record of the result. A gene typing result does not expire, and years later it can save a clinician from ordering a test again or from missing a connection between symptoms that appear unrelated on the surface.
No, HLA-B27 is not a single sequence, it is a family of closely related subtypes. Research suggests that subtypes differ in how strongly they are associated with spondyloarthritis, with the widely distributed B*2705 showing a clear association while certain subtypes found in specific populations show a weak association or none 7.
This matters for interpretation in two ways. First, population background influences how informative a positive result is, because both the frequency of the variant and the mix of subtypes differ between populations. Second, most routine laboratory reports simply state positive or negative without naming the subtype, since subtype resolution usually requires a specific DNA based request and is ordered only when a specialist thinks it will change something.
Copy number is a related question. You can carry one copy of the variant or two, one from each parent. Standard reporting does not usually distinguish them, and for most clinical purposes the distinction does not change what happens next.
The honest summary is that subtype and copy number refine a risk estimate at the margins. They do not convert a risk marker into a diagnosis. Whatever the subtype, the decisions that follow are still driven by what the person describes, what the examination shows and what imaging finds.
It is a standard blood draw with no fasting and no special preparation, and because your genotype does not change, it is a one time test. The sample is usually collected into a tube rich in anticoagulant, since some methods need intact cells.
Laboratories use two main approaches. Flow cytometry uses antibodies that bind the HLA-B27 molecule on the surface of white blood cells and reads the signal cell by cell. DNA based typing looks directly at the gene sequence. Both report the same practical output, positive or negative, sometimes worded as detected or not detected. Occasionally a flow cytometry result is ambiguous because related HLA molecules are structurally similar, and in that case a laboratory may confirm with a DNA based method.
Two limits are worth holding onto. The result does not move with symptoms, so repeating it during a flare tells you nothing new. And it is not a measure of inflammation, so it cannot indicate whether anything is active right now. That is the job of other markers, imaging and clinical assessment.
Timing and recent illness do not affect the result, which makes it an easy test to add to an existing blood draw. What does need care is interpretation, because a result reported in isolation is easy to over read in either direction. A copy of the report belongs in your own records.
C-Reactive Protein is a general blood marker of inflammation, frequently checked alongside a positive gene result to see whether inflammation is currently measurable. It is produced by the liver and rises with inflammation anywhere in the body, so it cannot point to a cause on its own. A value inside the standard range does not rule out active inflammatory back pain, and a raised value does not confirm spondyloarthritis, since infection, injury, recent intense exercise and body composition all move it. Its value lies in trend and context, especially when the same laboratory method is used over time and the number is read next to symptoms. For how the test works, how it is reported and how to read a single value, see the C-Reactive Protein guide.
The useful companions are general inflammation markers plus imaging of the sacroiliac joints, because the gene result answers a question about risk while those answer questions about what is happening now. A clinician decides which of them are appropriate.
| Marker | What it reflects | Reference range |
|---|---|---|
| C-Reactive Protein (CRP) | General inflammation, rises and falls relatively quickly | Typical lab reference range 0 to 3 mg/L. FitScript optimal range 0 to 1 mg/L |
| ESR | How quickly red cells settle, a slower moving inflammation signal | Varies by lab, age and sex |
| Complete blood count | Anaemia or raised platelets that can accompany long running inflammation | Varies by lab, age and sex |
These are typical lab reference ranges, and they vary by laboratory, age and sex, so read your own report's ranges. FitScript's optimal ranges are optimization targets used for health optimization, not diagnostic cut offs.
Imaging usually matters more than any of these. Plain radiographs of the sacroiliac joints can show structural change that has built up over years, while MRI can show active inflammation in bone that radiographs miss, which is why it is often used when symptoms are suggestive and radiographs look normal. Examination for restricted spinal movement, chest expansion and tenderness at tendon insertions adds information no blood test provides.
FitScript's membership covers 150+ biomarkers tested per year, and Atlas, FitScript's AI health advisor, reads those results together rather than one line at a time, with any clinical decision left to a licensed provider.
Less than people expect. A negative result lowers the probability of axial spondyloarthritis in someone with back pain, but it does not exclude it, because a meaningful share of people with the condition do not carry the variant. Diagnosis rests on the symptom pattern, the examination and imaging, with the gene result acting only as a supporting item.
The practical consequence is that a negative result should never end an investigation that symptoms justify. If back pain follows the inflammatory pattern, if it has persisted for months, if morning stiffness is prolonged, or if there are associated features such as recurrent eye inflammation, heel pain or gut symptoms, those findings keep the question open regardless of the typing result.
The mirror image is equally important. A positive result in someone whose back pain is clearly mechanical does not convert that pain into spondyloarthritis. Carrying the variant is common enough that it will often turn up by coincidence in people whose symptoms have an ordinary explanation, and over reading it can send an assessment down the wrong path.
This is the core discipline with any genetic risk marker. It adjusts the odds before the examination and the imaging, it does not replace either of them, and it is never a diagnosis by itself. If a result confuses you or seems to conflict with how you feel, that is a reason to ask your clinician to walk through the reasoning rather than to draw a conclusion alone.
Yes, HLA-B27 is inherited, and a parent who carries one copy passes it on to about half of their children on average. You inherit one copy of the HLA-B gene from each parent, and the versions behave co dominantly, meaning both are expressed on your cells rather than one masking the other.
What does not get inherited is a diagnosis. Relatives who share the variant share a shifted probability, not a shared outcome, and most of them will remain well. Families often include one person with clear spondyloarthritis and several carriers who have never had a symptom, which is exactly what you would expect from a risk marker that needs other contributing factors to matter.
For that reason, testing relatives who have no symptoms rarely changes anything useful. A positive result in a healthy relative cannot be acted on and can create worry out of proportion to the information, while a negative result can create false reassurance if symptoms appear later. Whether testing makes sense for a particular family member is a decision for a clinician who knows that person's history.
The more valuable thing to share with family is the symptom list. Relatives who know that months of early morning back stiffness, a sudden painful red eye or persistent heel pain are worth mentioning to a clinician tend to get assessed earlier, which is where the practical benefit of knowing about the variant actually sits.
Book a conversation when a symptom pattern, not the gene result alone, suggests something is going on. The situations most worth raising include the following.
Bring the actual laboratory report, a short timeline of symptoms and any previous imaging. Those three things move an appointment faster than any description from memory.
This article is educational and is not medical advice. Discuss your results, your symptoms and any treatment with a clinician or licensed provider who can assess you directly, and never ignore a result that falls outside your laboratory's reference range.
A positive result means you carry a common inherited version of an immune gene, and most people who carry it stay well. It raises the odds of certain inflammatory conditions of the spine, joints and eyes, but it does not mean you have any of them. The sensible response is to learn which symptom patterns are worth reporting and to bring the result to your clinician if any of them appear.
No, your genes do not change, so the result holds for life and does not need repeating. Retesting during a flare will not show anything new, because the test reports whether you carry the variant, not how much inflammation you have. Keep a copy of the report in your own records so future clinicians do not reorder it.
No fasting or preparation is needed. It is a standard blood draw that can usually be added to another blood test appointment, and the timing of day, recent meals and recent illness do not affect the outcome. Your laboratory will specify the tube type it needs, which the phlebotomist handles.
A negative result lowers the likelihood of axial spondyloarthritis but does not rule it out, since a meaningful number of people with the condition do not carry the variant. If your back pain started before around age 45, has lasted more than three months, comes with long morning stiffness and improves with movement, that pattern still deserves assessment. Ask your clinician about examination and imaging of the sacroiliac joints.
Usually not, if they have no symptoms. Relatives of a carrier have a higher chance of carrying the variant, but a positive result in a healthy person cannot be acted on and a negative one can give false reassurance later. Sharing the symptom list with family is generally more useful than testing them, and a clinician decides whether testing makes sense in a particular case.
It is usually ordered by a primary care clinician, a rheumatologist or an eye specialist when symptoms raise the question. The laboratory reports it as positive or negative, and the clinician who ordered it puts that into context with your examination, your symptom history and any imaging. Any decision about next steps or management belongs to a licensed provider.
Yes, and this is common. General inflammation markers can sit inside the standard laboratory range even while symptoms are active, so a normal value does not mean nothing is happening. That is why clinicians rely on the symptom pattern, the physical examination and imaging rather than on blood markers alone.
Seek assessment promptly, on the same day where possible, and mention that you carry HLA-B27. Front of the eye inflammation needs examination with equipment only an eye clinician has, and delays matter. Describe when the symptoms started, whether vision has changed and whether this has happened before.